Orthovita to present Cortoss study results in Geneva

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Orthovita, Inc. will present a scientific paper of a study comparing treatment with Cortoss vertebroplasty to a PMMA bone cement in 42 patients with osteoporotic compression fractures at the European Society of Neuroradiology meeting in Geneva.

Preliminary results suggest Cortoss may provide pain relief similar to PMMA while using about 40% less injected material than PMMA, the company said in a news release.

The complete pivotal study will enroll 243 patients, two-thirds of whom will be randomized to receive Cortoss vertebroplasty and one-third of whom will be randomized to receive to PMMA.

Orthovita is a biosurgery company located in Malvern, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.